Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2016-12-15 Board/Management Inform…
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content includes the promotion of a company officer (John McCabe) and an amendment to his employment agreement, which falls under management changes. Additionally, there is a corporate presentation attached as an exhibit, but the main body focuses on management changes rather than the presentation itself. The document length is 4266 characters, which is relatively short and typical for an 8-K announcing management changes. Therefore, the most appropriate classification is Board/Management Information (MANG).
2016-12-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 15, 2016. It includes a Regulation FD Disclosure about a poster presentation at a conference, which is furnished as an exhibit. The document does not contain financial statements or detailed financial data but rather a disclosure of a presentation event. The length is 2909 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories like Annual Report, Earnings Release, or Investor Presentation.
2016-11-15 English
SC 13G
Major Shareholding Notification
2016-11-09 English
FORM 4
Director's Dealing
2016-11-08 English
FORM 4
Director's Dealing
2016-11-07 English
FORM 4
Director's Dealing
2016-11-07 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.